Axon Announces Winning EU CRAFT Project Funding
[Groningen, NL. Jan, 2003] Axon Biochemicals BV, The Netherlands (refer to Axon) announced that:
EU granted Axon Biochemicals BV together with two other SMEs one CRAFT project (namely DOPATAGO, QLK6-CT-2002-71137) to develop GMC1111 and its related products as potential drug candidates for treating Parkinson disease or Schizophrenia.
Axon is a medicinal chemistry company, incorporated in the Netherlands in 1999. Axon conducts research in developing novel drug candidates in the CNS field and has invested for self-owned intellectual properties such as patents at national phase. Together with EU, government institutions, and pharmaceutical companies, Axon is now actively involved in several drug discovery programs from pre-clinic to Phase I. Axon is also an independent contract research organization providing high quality services in medicinal chemistry research. The company is specifically involved in rapid synthesis of drug standards and in contract research on drug design and synthesis. The company, with its experienced medicinal chemists in front-line drug research, offers the power of outsourcing research to the pharmaceutical companies in the world.